Orally Administered Activated Charcoal as a Medical Countermeasure for Acute Radiation Syndrome in Rats

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10045/114287
Información del item - Informació de l'item - Item information
Título: Orally Administered Activated Charcoal as a Medical Countermeasure for Acute Radiation Syndrome in Rats
Autor/es: Snezhkova, Elisaveta | Rodionova, Natalia | Bilko, Dennis | Silvestre-Albero, Joaquín | Sydorenko, Alexey | Yurchenko, Olga | Pakharenko, Marharyta | Alavijeh, Mo | Bardakhivska, Kvitoslava | Riabchenko, Natalia | Nikolaev, Vladimir
Grupo/s de investigación o GITE: Materiales Avanzados
Centro, Departamento o Servicio: Universidad de Alicante. Departamento de Química Inorgánica | Universidad de Alicante. Instituto Universitario de Materiales
Palabras clave: Activated charcoal | Enterosorbent | Acute radiation sickness | Rats
Área/s de conocimiento: Química Inorgánica
Fecha de publicación: 2-abr-2021
Editor: MDPI
Cita bibliográfica: Snezhkova E, Rodionova N, Bilko D, Silvestre-Albero J, Sydorenko A, Yurchenko O, Pakharenko M, Alavijeh M, Bardakhivska K, Riabchenko N, Nikolaev V. Orally Administered Activated Charcoal as a Medical Countermeasure for Acute Radiation Syndrome in Rats. Applied Sciences. 2021; 11(7):3174. https://doi.org/10.3390/app11073174
Resumen: Activated charcoal (AC) can be taken orally as enterosorbent for treatment of pathological states related to exogenous and endogenous intoxications. Synthesized granulated AC with a highly developed active surface (SBET ~2700 m2/g) was used as a medical countermeasure (MCM) to acute radiation sickness (ARS) in rats after total body X-ray irradiation. AC demonstrates positive results in ARS treatment, as expressed in, (i) a decrease in body weight loss, (ii) a protection of bone marrow (BM) cells colony formation capacity, (iii) a reduction of BM chromosomal aberrations and small intestine and spleen tissue damage, (iv) an amelioration of white blood cell count, and (v) a mitigation of superoxide ion generation rate in the liver. AC oral prescription seems to be perspective modality of ARS treatment.
Patrocinador/es: This research was funded by H2020-MSCA-RISE-2016 project, grant number 734641 acronym NanoMed.
URI: http://hdl.handle.net/10045/114287
ISSN: 2076-3417
DOI: 10.3390/app11073174
Idioma: eng
Tipo: info:eu-repo/semantics/article
Derechos: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Revisión científica: si
Versión del editor: https://doi.org/10.3390/app11073174
Aparece en las colecciones:INV - LMA - Artículos de Revistas
Investigaciones financiadas por la UE

Archivos en este ítem:
Archivos en este ítem:
Archivo Descripción TamañoFormato 
ThumbnailSnezhkova_etal_2021_ApplSci.pdf3,27 MBAdobe PDFAbrir Vista previa


Este ítem está licenciado bajo Licencia Creative Commons Creative Commons